technetium-tc-99m-exametazime and Multiple-Myeloma

technetium-tc-99m-exametazime has been researched along with Multiple-Myeloma* in 2 studies

Other Studies

2 other study(ies) available for technetium-tc-99m-exametazime and Multiple-Myeloma

ArticleYear
Multiple myeloma showing increased accumulation of Tc-99m hexamethylpropylene amine oxime on brain SPECT.
    Clinical nuclear medicine, 2000, Volume: 25, Issue:6

    The authors report a case of multiple myeloma with increased accumulation of Tc-99m hexamethylpropylene amine oxime (HMPAO) on brain SPECT. Tc-99m HMPAO is a lipophilic compound that freely passes through the intact blood-brain barrier and cell membrane and is rapidly converted to a hydrophilic form by glutathione and then retained in the neuron for several hours. In general, Tc-99m HMPAO shows decreased accumulation in brain tumors. However, some reports of increased accumulation in brain tumors, such as meningioma, glioblastoma multiforme, high-grade astrocytoma, pituitary adenoma, and multiple myeloma, have been published. The Tc-99m HMPAO uptake in these tumors has been attributed to tumor blood flow or glutathione contents within the tumor. With regard to uptake to Tc-99m HMPAO in multiple myeloma, the tumor size is considered to be an additional factor.

    Topics: Blood-Brain Barrier; Brain Neoplasms; Female; Humans; Middle Aged; Multiple Myeloma; Radiopharmaceuticals; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

2000
Avid uptake of technetium-99m-HMPAO by an intracranial plasmacytoma during carotid balloon test occlusion.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1995, Volume: 36, Issue:5

    A 56-yr-old woman was evaluated for removal of a tumor at the base of the skull. A test to determine the risk of carotid artery sacrifice was performed prior to surgery using carotid balloon occlusion of the left internal carotid artery and 99mTc-HMPAO perfusion scintigraphy during the occlusion. An unusual intense focus of increased uptake was seen at the site of the primary tumor in the left cavernous sinus. The tumor, found to be plasmacytoma at surgery, demonstrated only mild washout from 30 min to 2 hr after administration of 99mTc-HMPAO, with a tumor-to-cerebellum ratio of 1.6 and 1.5, respectively, and a tumor-to-contralateral cranial ratio of 2.5 and 2.4, respectively. Intracranial plasmacytoma shows good response to radiation therapy, and the differentiation of this tumor from other neoplasms is pertinent to the mode of treatment and surgical approach. Technetium-99m-HMPAO SPECT imaging may be a useful tool in distinguishing these tumors from other neoplasms at the base of the skull.

    Topics: Brain Neoplasms; Carotid Artery, Internal; Constriction; Female; Humans; Middle Aged; Multiple Myeloma; Organotechnetium Compounds; Oximes; Petrous Bone; Radiography; Skull Neoplasms; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1995